Thin Coverage of California Stem Cell Board Meeting


Media coverage of yesterday's $69
million in research awards and other matters involving the California
stem cell agency was nearly non-existent today.
That is not unusual, however, since the
$3 billion enterprise is not within the attention span of the
mainstream press and electronic outlets.
The California Stem Report could find
only two stories involving yesterday's actions. One by Ron Leuty
appeared in the San Francisco Business Times and was a look at the grant awards. The other appeared on Nature's website.
Unfortunately, Nature's lead was incorrect.
It said,

 "The California Institute of Regenerative Medicine
(CIRM)
voted on 24 May to accept a new strategic planwhich
shrinks or eliminates support for basic research, facilities and
training, while funneling more of its funds toward clinical
development."

The CIRM governing board actually put
off until at least July decisions on which programs to cut and which
to expand. Basic research is not likely, however, to take a major
hit, for a variety of reasons.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

'Sun Never Sets on CIRM' – California Agency Awards $69 Million to Researchers


The California stem cell agency today
awarded $69 million in grants, including the first involving a collaboration with researchers in China, but none of the awards went to California
biotech businesses.
The awards were made in the agency's
third translational round, which funds projects that are in the
initial stage of identifying drugs or cell types that could become
drug therapies.
CIRM originally allocated $95 million
for the round, but CIRM spokesman Kevin McCormack said that grant
reviewers determined that no applications beyond $69 million were
worthy of funding.
The CIRM governing board overturned a negative
reviewer decision on one grant after the scientist – W. Douglas
Boyd
of UC Davis -- filed an appeal. The appeals of two other
researchers, including one from a San Diego business, were not successful (see here
and here).
CIRM did not disclose the number of
applications from businesses. The agency has been sharply
criticized for failing to fund businesses in a substantial way.
The approved grants involve
collaboration with researchers in Australia and Germany as well as
China. The collaborations are based on agreements worked out earlier
by CIRM with overseas groups, which fund their own countries' researchers. No CIRM cash is involved, according to the agency.
CIRM President Alan Trounson, a native
of Australia and researcher there until joining the stem cell agency,
said in a press release,

"The sun now never sets on the
CIRM collaborative projects..."

The news release also said,

 "The
Chinese Ministry of Science and Technology has committed roughly
$850,000 in collaboration with a team at UCSF to study liver failure.
This is the stem cell agency’s first joint effort with scientists
in China, which is home to a fast-growing stem cell research
community."

The UCSF liver team is led by Holger
Willenbring
, whose goal is "to develop a source of autologous
therapeutic cells for patients with liver disease who otherwise would
require a liver transplant," according to the CIRM review summary.
The agency did not spell out the details of how the collaboration
would work.
All of the winning applicants, with the
exception of a Salk researcher, work for institutions linked to at
least one of the 29-members of the CIRM governing board. CIRM
directors, however, are barred from voting or even discussing applications in which CIRM attorneys have determined there is a conflict
of interest.
You can find the names of all the successful applicants in the CIRM news release.    

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

‘Sun Never Sets on CIRM’ – California Agency Awards $69 Million to Researchers


The California stem cell agency today
awarded $69 million in grants, including the first involving a collaboration with researchers in China, but none of the awards went to California
biotech businesses.
The awards were made in the agency's
third translational round, which funds projects that are in the
initial stage of identifying drugs or cell types that could become
drug therapies.
CIRM originally allocated $95 million
for the round, but CIRM spokesman Kevin McCormack said that grant
reviewers determined that no applications beyond $69 million were
worthy of funding.
The CIRM governing board overturned a negative
reviewer decision on one grant after the scientist – W. Douglas
Boyd
of UC Davis -- filed an appeal. The appeals of two other
researchers, including one from a San Diego business, were not successful (see here
and here).
CIRM did not disclose the number of
applications from businesses. The agency has been sharply
criticized for failing to fund businesses in a substantial way.
The approved grants involve
collaboration with researchers in Australia and Germany as well as
China. The collaborations are based on agreements worked out earlier
by CIRM with overseas groups, which fund their own countries' researchers. No CIRM cash is involved, according to the agency.
CIRM President Alan Trounson, a native
of Australia and researcher there until joining the stem cell agency,
said in a press release,

"The sun now never sets on the
CIRM collaborative projects..."

The news release also said,

 "The
Chinese Ministry of Science and Technology has committed roughly
$850,000 in collaboration with a team at UCSF to study liver failure.
This is the stem cell agency’s first joint effort with scientists
in China, which is home to a fast-growing stem cell research
community."

The UCSF liver team is led by Holger
Willenbring
, whose goal is "to develop a source of autologous
therapeutic cells for patients with liver disease who otherwise would
require a liver transplant," according to the CIRM review summary.
The agency did not spell out the details of how the collaboration
would work.
All of the winning applicants, with the
exception of a Salk researcher, work for institutions linked to at
least one of the 29-members of the CIRM governing board. CIRM
directors, however, are barred from voting or even discussing applications in which CIRM attorneys have determined there is a conflict
of interest.
You can find the names of all the successful applicants in the CIRM news release.    

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Stem Cell Agency Board Sticks with More Financial Disclosure


The governing board of the $3 billion
California stem cell agency today rejected a proposal that would have
restricted transparency surrounding the financial interests of its
directors and top executives.

On a unanimous voice vote, the board
decided it would stick with the more complete disclosure rules that it
has operated under since 2005. CIRM staff had offered changes that would have narrowed the amount of economic
information that the board members and the executives would have been
required to disclose.
The directors' Governance Subcommittee, however, on May 3 rejected the plan. Sherry Lansing, a former
Hollywood film studio CEO and chair of the subcommittee, said at the time,

"I personally feel strongly that
because of CIRM's unique mission and the agency's incredibly
long-standing commitment to transparency, i believe that we should
continue to set an example by requiring the broadest disclosure for
members of the board and high level staff."

Retention of existing disclosure
rules comes at a time when more conflicts may arise. The agency is
moving to engage the biotech industry more closely as it pushes to
develop stem cell therapies. Already one case of conflict has arisen this
year dealing with industry. It involves a "special advisor"
to CIRM who was nominated to become director of a firm sharing in a
$14.5 million grant. She also was working for the firm. (See here and
here.)
The CIRM board also has built-in
conflicts of interest, written into the law by Proposition 71, which
created the agency. About 92 percent of the $1.3 billion awarded so
far has gone to institutions tied to members of the CIRM governing
board. Board members are not permitted, however, to vote on or
discuss grants to their institutions. But it is fair to say that if
California voters had foreseen that nearly all of the grants would
have gone to directors' institutions, they would not have
approved creation of the stem cell agency.
As the California Stem Cell Report remarked earlier, it is a good
move for CIRM to retain more transparency rather than less. As one of
the Moss Adams staffers said today – in a different context –
during the presentation of the first-ever performance audit of CIRM,

"When people have to fill a void
in information, they assume the worst."

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

California Stem Cell Agency Launches Five-Year Push for Cures


The $3 billion California stem cell
today officially embarked on a course that will mean closer ties to
the biotech industry in hopes of fulfilling the campaign promises to voters to
turn stem cells into cures.

On a unanimous voice vote, directors approved
changes in the seven-year-old agency's strategic plan. The action
will likely mean less money for some activities that enjoyed more cash in the past,  but directors put off action until at least late July.  The plan also sets the course for what may be the last years of life
for the unprecedented state research program. Authorization to borrow
more money (state bonds) for its grants will run out in about 2017.

During a brief discussion of the plan, which has been debated for some months, CIRM Director Jeff Sheehy noted that the agency has now entered "the realm of trade-offs."  Ellen Feigal, CIRM's senior vice president for research and development, told the board that the plan will require hard decisions and sharp focus on priorities. 

Among other things, for first time CIRM overtly set a goal of creating 20 programs that include outside
investment that focus on products. Another five-year goal explicitly calls for financing at least 10 therapies in early-phase
clinical trials, affecting at least five diseases. Overall, the plan seeks to achieve clinical proof-of-concept for stem cell therapies.

In contrast to the Proposition 71
campaign rhetoric, CIRM's strategic plan acknowledges that developing therapies takes a very long time,
often decades.
Two scenarios were presented to the
board for spending the agency's remaining $836 million for grants and
loans. One would allocate $506 million for development research, $195
for translational research and $135 million for basic research, but
nothing for training and "facilities/core resources."
The other scenario calls for $486
million for development research, $160 million for translational
research, $105 for basic research, $60 million for training and $25
million for "facilities/core resources."

The first scenario would mean a $85 million cut in training and shared lab programs – cash that helps to finance researchers and that benefits the many institutions that have representation on the CIRM board.

The board put off action on either scenario after CIRM President Alan Trounson said he wanted more time to prepare a complete analysis of the scenarios. 

The plan also calls for creation of a
platform to enable grantees, disease foundations, venture capitalists
and others to purse CIRM's mission when its state bond funding runs
out. The possibility exists that another bond measure would be submitted to voters. But in either case, CIRM will need a solid record to attract support. 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

CIRM Directors Pleased with Performance Audit Findings


The $3 billion California stem cell
agency received a "very favorable" performance audit report
compared to other government agencies, CIRM directors were told
today.

Representatives of Moss Adams, which
was paid $234,944 by CIRM for the study, made the comments during a
presentation today to the agency's 29 directors. During their
comments, CIRM executives and directors focused on the favorable
aspects of the findings of the six-month study.
CIRM Chairman J.T. Thomas said the
report showed that CIRM is "doing better than being on the right
track." Co-vice chairman Art Torres said,

 "Comparatively we
have done very well."

The report praised the professionalism
of the CIRM staff – "a high caliber group" – and noted
the seven-year-old agency is both "ramping up and ramping down"
at the same time – a reference to the end of state bond funding for
CIRM in 2017.
Prior to the presentation, CIRM
President Alan Trounson said the staff would review the findings and
come up with a plan for the board at its July meeting. The agency is
already implementing some of the recommendations.
The audit was required by a recent
state law that also allowed CIRM to hire more than 50 persons, a cap
imposed by Proposition 71, which created the agency. The audit found a need for improvement in 27 areas and made recommendations. Of the 20 recommendations with the highest priority,
half involved how CIRM manages its information, much of which is
needed for good decision-making. The audit did not assess the
scientific performance of the agency.
The Moss Adams report, performed by the
Seattle firm's San Francisco office, said,

"CIRM board members and senior
management do not receive regularly updated, enterprise-level
performance information. The ability to evaluate performance against
strategic goals is critical to effective leadership and program
monitoring, evaluation, and reporting. CIRM does not currently have a
formal performance reporting program."

In addition to decision-making
information, Moss Adams called for improvements in the agency's
long-troubled grants management system, better grant outcome
tracking, development of a results-based communications plan,
creation of a comprehensive, formal business development plan,
formulation of a comprehensive information technology plan that would
include steps to establish clear responsibility for CIRM's website
and improved monitoring of invention disclosure forms from grantee
institutions.
Last week, in a long overdue move, the
agency hired a director for information technology, who is expected
to solve many of the problems cited in the audit.
State law requires another performance audit in a few years. 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Live Coverage of Tomorrow's California Stem Cell Meeting


The California Stem Cell Report will
provide live coverage of tomorrow's meeting of the governing board of
the $3 billion California stem cell agency. Directors are expected to
make major decisions about the agency's future direction, hear the results
of the first-ever performance audit and award about $95 million in
grants or loans.

The meeting will be held near the San
Francisco airport with another public teleconference location at UC
San Francisco
. Los Angeles will also have two public teleconference
locations. Another will be in La Jolla.
The meeting will be audiocast live on
the Internet, which the California Stem Cell Report will monitor from its
base in Panama near the Pacific entrance to the Panama Canal.
Instructions for listening in on the
audiocast can be found on the agenda along with specific addresses
for the public teleconference locations. The meeting is scheduled to
begin at 9 a.m. PDT.  

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Live Coverage of Tomorrow’s California Stem Cell Meeting


The California Stem Cell Report will
provide live coverage of tomorrow's meeting of the governing board of
the $3 billion California stem cell agency. Directors are expected to
make major decisions about the agency's future direction, hear the results
of the first-ever performance audit and award about $95 million in
grants or loans.

The meeting will be held near the San
Francisco airport with another public teleconference location at UC
San Francisco
. Los Angeles will also have two public teleconference
locations. Another will be in La Jolla.
The meeting will be audiocast live on
the Internet, which the California Stem Cell Report will monitor from its
base in Panama near the Pacific entrance to the Panama Canal.
Instructions for listening in on the
audiocast can be found on the agenda along with specific addresses
for the public teleconference locations. The meeting is scheduled to
begin at 9 a.m. PDT.  

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Michael J. Fox Backs Away From Stem Cell Cure for Parkinson's


It was not exactly a case of "Back
to the Future,
" the hit movie starring Michael J. Fox,
but it did offer a reflection on the past.

It involves the actor's
changing views on stem cell research in connection with Parkinson's
disease, which he has had since the 1990s.
Fox's 2004 Ad
Early on, Fox was well-known for his
support of human embryonic stem cell research. ABC News
recently described him as having become "one of the country’s
most visible advocates for stem cell research." In California, Fox was a prominent promoter of the ballot initiative, Proposition 71,
that created the $3 billion California stem cell agency in 2004. "
He filmed a TV commercial that was
aired widely during the 2004 campaign to create the stem cell agency,
declaring,

 "It could save the life of someone you love."

Today he is considerably less
confident. In an interview last week with ABC, he cited "problems
along the way." Fox said,

“It’s not so much that [stem cell
research has] diminished in its prospects for breakthroughs as much
as it’s the other avenues of research have grown and multiplied and
become as much or more promising. So, an answer may come from stem
cell research but it’s more than likely to come from another area.”

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Michael J. Fox Backs Away From Stem Cell Cure for Parkinson’s


It was not exactly a case of "Back
to the Future,
" the hit movie starring Michael J. Fox,
but it did offer a reflection on the past.

It involves the actor's
changing views on stem cell research in connection with Parkinson's
disease, which he has had since the 1990s.
Fox's 2004 Ad
Early on, Fox was well-known for his
support of human embryonic stem cell research. ABC News
recently described him as having become "one of the country’s
most visible advocates for stem cell research." In California, Fox was a prominent promoter of the ballot initiative, Proposition 71,
that created the $3 billion California stem cell agency in 2004. "
He filmed a TV commercial that was
aired widely during the 2004 campaign to create the stem cell agency,
declaring,

 "It could save the life of someone you love."

Today he is considerably less
confident. In an interview last week with ABC, he cited "problems
along the way." Fox said,

“It’s not so much that [stem cell
research has] diminished in its prospects for breakthroughs as much
as it’s the other avenues of research have grown and multiplied and
become as much or more promising. So, an answer may come from stem
cell research but it’s more than likely to come from another area.”

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Third Researcher Appealing Grant Rejection to Stem Cell Agency Board


The director of robotics and biosurgery
at UC Davis is appealing rejection of his application for a
$4.9 million grant from the California stem cell agency.

The scientist, W. Douglas Boyd,
noted that his proposal was given a scientific score of 67, which was
one point below the cutoff for most grants approved by CIRM's
Grants Working Group
. Thirteen grants fell in the 68 to 53
range, including Boyd's. Reviewers approved four in that range,
including two with scores of 53.
Boyd's letter was brief, focusing on a
letter of support from an Indiana firm, Cook Biotech, Inc.,
that would supply the "material and technical expertise to
create a new bioengineered cardiac patch
material."
The appeal letter, along with other
appeals(see here and here), will be given to CIRM directors in the agenda material for their meeting tomorrow in San Francisco. The
board does not have to act on the petitions or discuss them.
Researchers can also appear before the board to make a case.

Claire Pomeroy, CEO of the UC
Davis Health
Systems, is a member of the CIRM board. She
will be barred from taking part in any discussion of Boyd's
application or voting on it.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Stem Cell Agency Hires Tech Chief to Solve a Myriad of Problems


In a move that was long overdue, the $3
billion California stem cell agency last week hired a director of
information technology to straighten out key problems ranging from
its grants management system to how it handles its website.

The new hire comes as the CIRM
governing board faces the results of its first-ever performance audit, which is markedly critical of how the agency handles its
information. Half of the audit's 20 highest priority recommendations for improvement focus on information deficiencies, including
critical information necessary for CIRM executives to determine the
agency's performance.
Solving those problems will fall on
the shoulders of Bill Gimbel, who is no stranger to CIRM. He has been
working with the agency as an information technology advisor since
2010 through a contract with Infonetica, Inc., of Pleasanton, Ca., according to CIRM spokesman Kevin McCormack.  Gimbel is now the first staff person in a chief technology position at CIRM since October 2007, when about 25 percent of CIRM employees left.
Bill Gimbel
A graduate of MIT, Gimbel, who will be
paid $180,000 annually, has a broad range of experience in computer
technology and software dating back to 1992. According to his
Linkedin web site, he was most recently director of IT at Infonetica.
He lists himself as owner of aptReader, an app for reference books.
He has also worked for LearningExpress and Scholastic, Inc.
The stem cell agency has been wrestling with information technology issues for years. The critical grants
management system has been an issue at least since 2007, when
directors were told its costs would not exceed $757,000. No figures
for the total spent since then have been made public by CIRM, which
is attempting to build a custom system, but the amount clearly and
easily surpasses the 2007 estimate, based on some of the outside
consulting costs. Although the agency hopes to resolve many of the
problems by the end of this calendar year, the grant system was the
target of considerable attention by Moss Adams, the firm that
prepared the performance audit.
Over the years, CIRM directors have received
intermittent, sketchy CIRM staff reports about the grants management
system, but the Moss Adams discussion is the most
comprehensive.
Among other things, the Moss Adams report said in bureaucratically delicate language,

 "Integration
of website content management has not been an integral part of the
GMS (grants management system) development process, which could
result in suboptimal operational efficiency and effectiveness.

"Grants management system
development is effectively managed at a tactical level, but it lacks
dedicated, strategic governance and oversight, which has resulted in
an elongated development process and requirements conflicts."

Moss Adams said,

"The new grants management system
intellectual property module, currently under development, does not
include provisions to address commercialization activity."

The performance audit additionally
said,

"CIRM board members and senior
management do not receive regularly updated, enterprise-level
performance information. The ability to evaluate performance against
strategic goals is critical to effective leadership and program
monitoring, evaluation, and reporting. CIRM does not currently have a
formal performance reporting program."

Moss Adams continued on other
information technology topics:

"Data and document access are
inefficient as a result of CIRM operating without a document
management system.....In most cases, CIRM staff cannot access
information without human interface. Information is stored in
multiple locations, which are not linked or indexed."

The audit said that the agency has
tried to solve its information problems without a plan. 

 "CIRM’s
information system needs have been met by a variety of tools,
including in-house developed applications, off-the-shelf
applications, databases, and spreadsheets, most of which are not
integrated," the audit stated.

One of the effects of all this is much
wasted time when CIRM's tiny staff tries to extract information from
the hodge-podge of systems. It is time that cannot be spared as the
workload increases in the next few years, as it is certain to do. 
CIRM's 29-member board is scheduled to consider the performance audit at its meeting this Thursday. 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Dr Topol to med students: "When I was in medical school, the term "digital" was reserved for the rectal examination"

Here are some excerpts from the Baylor College of Medicine commencement address by Dr. Eric Topol, director of the Scripps Translational Science Institute, delivered yesterday, May 22, 2012. This should be a required reading for everyone involved in healthcare, which is basically everybody because each and every one of us will be a patient one day.

Eric Topol to medical students: "When I was in medical school, the term "digital" was reserved for the rectal examination."

"You sleep with your cell phone and prize it right up there with food and water. We have evolved to a new species of man. We are Homo distractus!"

The benefits of digital medicine are clear to Dr. Topol who shares the story of a patient he saw last week: "I asked him to put his fingers on the 2 sensors on the back of my iPhone case so I could do his electrocardiogram—ECG—that was normal. And free, by the way. Then instead of using a stethoscope to listen to his heart, I used a portable pocket-sized high-resolution ultrasound device and within a minute I could see every heart structure—the heart muscle thickness and function, the valves, the size of the 4 chambers. Why would I ever listen for lub-dub when I can see everything? I haven't used a stethoscope for over 2 years to listen to a patient's heart."

Here is Eric Topol's presentation at Health at Google:

References:

Baylor College of Medicine commencement address by Dr. Eric Topol, director of the Scripps Translational Science Institute

Comments from Twitter

Quoc-Dien Trinh, MD @qdtrinh: Makes it sound cool. “@DrVes: Dr Topol to med studs: When I was in med school, the term "digital" was reserved for the rectal examination"

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feeds.feedburner.com/CasesBlog

Hemophilia educational videos by CDC

Hemophilia belongs to a family of inherited lifelong bleeding conditions that prevent blood from clotting properly. Patients with these disorders bleed for longer than normal, either as a result of injury or spontaneously without an external cause.

The severity of bleeding depends on the amount of clotting factor that is missing or not functioning properly, which in hemophilia A and B - the most common types of hemophilia - is the coagulation factors VIII and IX, respectively.

In addition to external bleeding, patients more commonly have internal bleeding around the joints and muscles, which can be extremely painful and cause permanent disability. Bleeding into major organs such as the brain is especially difficult to manage and can be fatal.

Here are 2 hemophilia educational videos by CDC:  Playing it Safe With Hemophilia: Friends with hemophilia talk about playing sports growing up and the importance of making smart decisions.

Starting the Conversation: Hemophilia. How to talk to your friends about hemophilia. A group of friends ask their friend Billy questions about his hemophilia:

Hemophilia care has undergone substantial improvements during the past 40 - 50 years. Early clotting factor concentrates were not sufficiently refined to enable self-administered treatment at home until the 1970s.

Long-term substitution therapy (prophylaxis) of the missing clotting factor is the recommended treatment in severe hemophilia. The major side-effect of treatment, development of inhibitors to the infused concentrate, is the main threat to the health of patients.

Mnemonic: Differential Diagnosis of Bleeding Disorders: F-CAP

Fibrinolysis - tPA
Coagulopathy - hemophilia, vWD
Angiopathy - conditions affecting blood vessels, e.g. Osler-Weber-Rendu syndrome
Platelets - thrombocytopenia or thrombocytopathia

Initial diagnostic tests = 3P:

Platelets
PT - INR
PTT

References:

http://www.cdc.gov/NCBDDD/video/Hemophilia_sports/index.html

http://www.cdc.gov/NCBDDD/video/Hemophilia_Friends/index.html

Making haemophilia a global priority - The Lancet, 2012.

Modern haemophilia care - The Lancet, 2012.

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feeds.feedburner.com/CasesBlog

Mayo Clinic now offers Patient App: access to personal medical record, appointment schedule and more

The Mayo Clinic Patient app allows access to the latest news, publications, and health information from Mayo Clinic. Mayo Clinic patients also have access to their personal medical record, appointment schedule and other services using their Patient Online Services account.

The Mayo Clinic Patient app provides local community information, including directions to local restaurants, entertainment, and more. http://youtu.be/UAymmf5ZUNo

Posted at Clinical Cases and Images. Stay updated and subscribe, follow us on Twitter and connect on Facebook.


Source:
http://feeds.feedburner.com/CasesBlog

Plate my lungs with nickel? No thank you, sir

Nickel tetracarbonyl

Nickel tetracarbonyl - highly unpleasant, but extremely useful (Credit: Wikimedia commons/ Benjah-bmm27)

For my contribution to Sciencegeist’s toxic blog carnival, I decided to write about a decidedly enigmatic compound. Nickel tetracarbonyl is a transition metal complex but also a foul-smelling (and, given the context of this blog post, naturally highly toxic) gas. These are not generally two molecular properties that coincide. It also forms quite easily when nickel metal comes into contact with carbon monoxide.

Having not personally worked with it, I nevertheless respect and admire nickel tetracarbonyl from afar. However, this is a compound which can provoke intensely personal reactions from people who have had the opportunity to get a little more hands-on. I came across possibly one of the most vivid of these in our Chemistry in its element podcast series when Bernie Bulkin described his initiation into a lab working on metal carbonyl complexes:

‘One of the first things I was given to read when I started was the summary of the toxicological effects of nickel carbonyl.  I learned, with some concern, that at 30ppm it was certainly fatal, and even a significantly lower dose of 3ppm caused death in 50% of a group of test animals.

‘When you breathe it in, it decomposes, giving you a dose of carbon monoxide and depositing some nickel on your lungs. If you survive the first few hours, the nickel causes a form of pneumonia, coughing, breathlessness, extreme fatigue.  This lasts for several days, often resulting in cardiovascular or renal failure and death.  I was relieved to find that the safety precautions in the lab were extremely rigorous.’

The concept of receiving a bolus dose of carbon monoxide – deadly enough in its own right as described in Patrick’s blog yesterday – plus the added spice of nickel-plated lungs, was enough to imprint an instant respect for the compound in my mind.

So why on Earth might we want to make or use this compound, given its extreme potential to cause harm?

Nickel as a metal is industrially important – it is hard, shiny and reasonably resistant to corrosion (except by carbon monoxide of course…). Alloyed into steel or plated over the surface it endows the metal with these useful properties too, so much so that it was used to make coins (before being largely replaced by iron, which is cheaper and doesn’t cause the same kind of skin irritation that some people experience when handling nickel). Some coins, particularly the US five-cent pieces known as ‘nickels’, still contain nickel alloyed with copper or plated on the surface of a steel blank.

Nickel’s hardness and corrosion resistance also makes it ideal as the basis for superalloys used to make jet engine turbine blades. These are generally grown as single crystals of the metal for optimum performance at the high temperatures and force loadings of a working jet engine.

So where does nickel carbonyl fit in?

Nickel is rarely found in ores on its own – it is usually combined with its transition metal neighbours iron and cobalt. In fact, the name nickel comes from colloquial German for ‘devil’ (think of ‘Old Nick’ in English folklore) and cobalt derives from the word for a gremlin or hobgoblin, reflecting their role as annoying impurities in iron ores. So a method for separating the metals would not only deliver the desirable nickel, but improve processes for purifying iron and cobalt as well.

Having discovered nickel carbonyl by accident, Ludwig Mond – a German chemist – found that nickel reacts with carbon monoxide much more quickly than does either iron or cobalt. As a savvy businessman, he realised the potential of this observation and, in the late 19th century, developed it into the Mond process for extracting nickel from mixed ores. Reacting impure nickel with CO releases it as gaseous nickel carbonyl and leaves behind the impurities. The nickel can then be reclaimed by heating the complex until it decomposes. This process is still used when the purest nickel (greater than 99.99% pure) is required.

From a research chemistry point of view, nickel complexes form a variety of useful catalysts. Many of these are prepared from nickel carbonyl in some form, owing to the ease of displacing the carbonyl ligands. However, the chemist aspiring to prepare such catalysts would be well advised to seek out alternative sources of nickel in which someone else has already done the carbonyl substitutions – nickel plated lungs and death by suffocation or pneumonia is certainly not to be recommended…

Phillip Broadwith

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

The silent killer

Over at Sciencegeist they’ve throw down the gauntlet and asked bloggers to write about their favourite toxic chemical as part of a carnival of toxins that also play important roles in everyday life. It’s all part of the campaign by chemists and bloggers alike against ‘chemophobia’ – an irrational fear of the chemicals we find all around us in everyday life or even the very word ‘chemical’. Recently there seems to have been a spate of these articles in newspapers with chemical-free labels even popping up in labs where they ought to be choosing their words with a little more care!

Canaries provided a CO early warning system for miners

So I’m going to kick off Chemistry World’s contribution to the carnival with carbon monoxide: the silent killer. It’s now pretty much common knowledge that this diatomic molecule can kill, thanks to television images of people committing suicide by gassing themselves with car exhausts (this is much less likely today as catalytic converters mop up and transform much of the CO in exhaust fumes) and public health campaigns highlighting the dangers of the gas in the home. But John Scott Haldane, the father of noted geneticist J B S Haldane, was the first to realise that this colourless, odourless gas was responsible for the deaths of many miners. The CO that killed these miners was the result of incomplete combustion of carbon during coal dust explosions. J S Haldane, belonging to that intrepid class of chemists that is all but extinct now, used himself as a guinea pig to investigate the effects of CO. By exposed himself to potentially lethal doses of the chemical, he discovered the dangers it posed, which led to the introduction of canaries in mines as early warning signals of danger. Good for miners, bad for canaries! You can hear more about J S Haldane in Chemistry World’s podcast on carbon monoxide.

CO’s killing power comes from its affinity for the haemoglobin in red blood cells, binding to it preferentially over oxygen to form carboxyhaemoglobin. People exposed to CO are figuratively drowning in air – there’s plenty of oxygen all around them but their bodies just can’t absorb enough of it. And, in a grisly twist, carboxyhaemoglobin is bright red, giving victims of CO poisoning a hale and hearty rosy hue.

Unsurprisingly, this has led to boilers, and the deadly gas they can produce, becoming inextricably linked in people’s minds with danger – to be guarded against in the home and on holiday. In the US alone, it is estimated that 40,000 people seek medical attention for CO poisoning each year, so it’s clear it’s still a serious problem.

That’s the dark side of CO, but is there a lighter side? Oddly enough, it was discovered in the 1990s that this deadly gas has a memorable and vital physiological function. It acts as a neurotransmitter in certain parts of the brain involved in long-term memory and has functions in many other parts of the body that are only just being understood. CO joins hydrogen sulfide and nitric oxide as another small and toxic gaseous molecule, which is a vital poison that our bodies both produce and need to function properly. As a result, companies like Alfama are now developing drugs that release CO in minute amounts to treat diseases involving inflammation and a range of other conditions. This turnaround in the way CO is now viewed really gives wings to the old axiom ‘the dose makes the poison’.

Patrick Walter

 

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

Chemistry in its element – potassium permanganate

 It’s a stalwart of the undergraduate lab and can still be found introducing kids to the joys of science in even today’s modest chemistry sets. But potassium permanganate is good for much more than pretty colours and redox titrations… in fact, it could well save your life. Brian Clegg praises our purple pal in this week’s Chemistry in its element podcast.

 

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

Cracking paper runs into authorship dispute

A couple of weeks ago Chemistry World ran a story on a cracking paper from a team in Korea. The researchers took inspiration from the way Egyptian stone masons cracked large stone blocks (they inserted a wedge into a hole and then soaked it with water, causing it to expand and crack the stone) to create a technique to make nanoscale cracks in a controlled manner. They did this by etching a guide of notches and grooves into a silicon substrate and then depositing silicon nitride on top. The notches and grooves create a pathway for cracks to propagate along and this technique could be very useful for electronic and microfluidic devices.

© Nature

However, it now turns out that there’s an authorship dispute. The PhD student who said that she did much of the legwork didn’t get a note on the author list, according to this story in the Korea Herald (h/t @naturenano). The leader of the research group, Nam Koo-hyun at Ewha Womans University, Seoul, told the Herald that he made it clear from the start that the PhD student wouldn’t get a credit and that doing experimental work ‘does not qualify one for authorship’. I’m not sure how other PhD students would feel about this! Plenty of people have received a name check for far less than carrying out the experimental work. What do you think the cut off point should be for getting an author credit?

Patrick Walter

Digg This  Reddit This  Stumble Now!  Share on Facebook  Bookmark this on Delicious  Share on LinkedIn  Bookmark this on Technorati  Post on Twitter  Google Buzz (aka. Google Reader)  

Source:
http://prospect.rsc.org/blogs/cw/?feed=rss2

BONE – Anatomy Illustrated

Josip Kelava BONE (5)

Josip Kelava BONE (4)

Josip Kelava BONE (3)

Josip Kelava BONE (2)

Josip Kelava BONE (1)

Extremely talented Melbourne-based designer, Josip Kelava, created this book featuring the master illustrators of the 16–19th centuries.

Josip says of the book,

… it focuses on the illustrator William Cheseldon who was an English surgeon and teacher of anatomy, and who was influential in establishing surgery as a scientific medical profession. His works, along with many other illustrators, have been redesigned to a modern style, incorporating typography as a sense of interaction with the illustrations.

I really enjoy Josip’s design sense and I highly recommend taking a look through the rest of his design work in his Behance portfolio.

 

Source:
http://feeds.feedburner.com/streetanatomy/OQuC